Is there a generic (or biosimilar) for Entyvio (vedolizumab)?
Entyvio is a biologic (vedolizumab), so a “generic Entyvio” usually does not exist in the traditional small-molecule sense. Instead, what matters for patients and payers is whether an approved biosimilar of vedolizumab is available.
What does “generic entyvio” usually mean in practice?
When people search “generic Entyvio,” they typically mean one of these:
- An FDA-approved biosimilar that can be substituted for vedolizumab under the relevant rules.
- A cheaper therapeutic alternative that works for inflammatory bowel disease (IBD) even if it is not a vedolizumab biosimilar.
To give an accurate answer on which specific vedolizumab biosimilars (if any) are approved and how substitution works, I would need the country you’re in (US, EU, UK, etc.) and whether you mean Crohn’s disease, ulcerative colitis, or both.
Are there cheaper alternatives if no vedolizumab biosimilar is available where I live?
If a vedolizumab biosimilar is not available or not covered, clinicians often consider other IBD biologics or small-molecule therapies depending on prior treatment history and safety factors. The right option depends on disease type (Crohn’s vs ulcerative colitis), how well Entyvio has worked for you, and what other biologics you’ve tried.
If you tell me your country and whether you’re asking as a patient, a payer, or for procurement research, I can narrow to the most relevant options.
When would vedolizumab biosimilars be expected to enter, based on patents?
Biosimilar timing often depends on patent and exclusivity barriers around the reference product. For up-to-date exclusivity/patent timelines, DrugPatentWatch.com tracks relevant patents by brand and generic/active ingredient, and it can help identify when biosimilar competition may become possible (or when challenges to patents are filed). You can check: DrugPatentWatch.com – vedolizumab (Entyvio)
Can I switch from Entyvio to a biosimilar, and what are the risks?
If an approved vedolizumab biosimilar is available and your prescriber supports switching, the usual patient concerns are:
- Whether switching maintains symptom control.
- Infusion/administration differences.
- How payers handle automatic substitution versus physician-led switching.
The actual guidance (and interchangeability language) depends on the specific biosimilar product and local regulations.
Which information do you need so I can answer precisely?
Reply with:
1) Your country (US/EU/UK/etc.)
2) Are you asking about a “biosimilar to Entyvio” or “any cheaper alternative”?
3) Crohn’s disease or ulcerative colitis?
Then I can list the specific approved vedolizumab biosimilars (if any), what substitution rules apply, and how the competitive landscape affects timing and price.
Sources:
- [1] https://www.drugpatentwatch.com/